Study of ZG005 in Patients With Advanced Solid Tumors
A phase 2 trial of ZG005 for Injection in advanced solid tumours, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, active and no longer recruiting.
Overview
Study of ZG005 in Patients With Advanced Solid Tumors is a phase 2 interventional study registered as NCT06927687 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 50 participants enrolled, started 2025-06-13 and due to reach its primary completion in 2027-05. Interventions recorded: ZG005 for Injection.
Similar pages
not linked directly; found by shared links- TrialStudy of ZGGS18 in Patients With Advanced Solid Tumors
Shares Suzhou Zelgen Biopharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Shares Suzhou Zelgen Biopharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of ZGGS34 in Participants With Advanced Solid Tumors
Shares Suzhou Zelgen Biopharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.